Brexit implications for British pharma ... A month on

23 July 2016
medical_legal_law_big

It is an indisputable fact that Brexit has sent shockwaves through the pharmaceutical and life science industries and although the exact extent of the fallout is not yet known, the impact is sure to be felt for many years to come.

Exactly a month on from one of the most significant votes in British history, the Pharma Letter takes a look at the immediate aftermath of the decision and some of the potential long term implications.

There are still many unanswered questions following Britain's historic vote to leave the European Union and a cloud of uncertainty, even fear, hangs heavy over British science.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical